# OPTIMUM (NCT03941860)

> Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03941860
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Multiple Myeloma
- Interventions: Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Computed Tomography; Ixazomib Citrate; Lenalidomide; Placebo Administration; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 1
- Primary outcome: Overall Survival (OS)

## Indexed commentary on OPTIMUM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=optimum-nct03941860